The synthesis and characterization of the15N‐labeled analogue of the mitochondrial calcium uptake inhibitor [Cl(NH3)4Ru(μ‐N)Ru(NH3)4Cl]3+(Ru265) bearing [15N]NH3ligands is reported. Using [1H,15N] HSQC NMR spectroscopy, the rate constants for the axial chlorido ligand aquation of [15N]Ru265 in pH 7.4 buffer at 25 °C were found to be
Oncostatin M (OSM) is a pleiotropic, interleukin-6 family inflammatory cytokine that plays an important role in inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer progression and metastasis. Recently, elevated OSM levels have been found in the serum of COVID-19 patients in intensive care units. Multiple anti-OSM therapeutics have been investigated, but to date no OSM small molecule inhibitors are clinically available. To pursue a high-throughput screening and structure-based drug discovery strategy to design a small molecule inhibitor of OSM, milligram quantities of highly pure, bioactive OSM are required. Here, we developed a reliable protocol to produce highly pure unlabeled and isotope enriched OSM from
- PAR ID:
- 10285840
- Publisher / Repository:
- Nature Publishing Group
- Date Published:
- Journal Name:
- Scientific Reports
- Volume:
- 11
- Issue:
- 1
- ISSN:
- 2045-2322
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
Abstract k 1=(3.43±0.03)×10−4 s−1andk 2=(4.03±0.09)×10−3 s−1. The reactivity of [15N]Ru265 towards biologically relevant small molecules was also assessed via this method, revealing that this complex can form coordination bonds to anionic oxygen and sulfur donors. Time‐based studies on these ligand‐binding reactions reveal this process to be slow relative to the time required for the complex to inhibit mitochondrial calcium uptake, suggesting that hydrogen‐bonding interactions, rather than the formation of coordination bonds, may play a more significant role in mediating the inhibitory properties of this complex. -
Abstract The composition of fluorescent polymer nanoparticles, commonly referred to as carbon dots, synthesized by microwave‐assisted reaction of citric acid and ethylenediamine was investigated by13C,13C{1H},1H─13C,13C{14N}, and15N solid‐state nuclear magnetic resonance (NMR) experiments.13C NMR with spectral editing provided no evidence for significant condensed aromatic or diamondoid carbon phases.15N NMR showed that the nanoparticle matrix has been polymerized by amide and some imide formation. Five small, resolved13C NMR peaks, including an unusual ═CH signal at 84 ppm (1H chemical shift of 5.8 ppm) and ═CN2at 155 ppm, and two distinctive15N NMR resonances near 80 and 160 ppm proved the presence of 5‐oxo‐1,2,3,5‐tetrahydroimidazo[1,2‐
a ]pyridine‐7‐carboxylic acid (IPCA) or its derivatives. This molecular fluorophore with conjugated double bonds, formed by a double cyclization reaction of citric acid and ethylenediamine as first shown by Y. Song, B. Yang, and coworkers in 2015, accounts for the fluorescence of the carbon dots. Cross‐peaks in a1H─13C HETCOR spectrum with brief1H spin diffusion proved that IPCA is finely dispersed in the polyamide matrix. From quantitative13C and15N NMR spectra, a high concentration (18 ± 2 wt%) of IPCA in the carbon dots was determined. A pronounced gradient in13C chemical‐shift perturbations and peak widths, with the broadest lines near the COO group of IPCA, indicated at least partial transformation of the carboxylic acid of IPCA by amide or ester formation. -
Abstract The Receptor for Advanced Glycation End products (RAGE) is a pattern recognition receptor that signals for inflammation via the NF‐κB pathway. RAGE has been pursued as a potential target to suppress symptoms of diabetes and is of interest in a number of other diseases associated with chronic inflammation, such as inflammatory bowel disease and bronchopulmonary dysplasia. Screening and optimization have previously produced small molecules that inhibit the activity of RAGE in cell‐based assays, but efforts to develop a therapeutically viable direct‐binding RAGE inhibitor have yet to be successful. Here, we show that a fragment‐based approach can be applied to discover fundamentally new types of RAGE inhibitors that specifically target the ligand‐binding surface. A series of systematic assays of structural stability, solubility, and crystallization were performed to select constructs of the RAGE ligand‐binding domain and optimize conditions for NMR‐based screening and co‐crystallization of RAGE with hit fragments. An NMR‐based screen of a highly curated ~14 000‐member fragment library produced 21 fragment leads. Of these, three were selected for elaboration based on structure‐activity relationships generated through cycles of structural analysis by X‐ray crystallography, structure‐guided design principles, and synthetic chemistry. These results, combined with crystal structures of the first linked fragment compounds, demonstrate the applicability of the fragment‐based approach to the discovery of RAGE inhibitors.
-
Abstract We report the recombinant preparation from
cells of samples of two closely related, small, secreted cysteine‐rich plant peptides: rapid alkalinization factor 1 (RALF1) and rapid alkalinization factor 8 (RALF8). Purified samples of the native sequence of RALF8 exhibited well‐resolved nuclear magnetic resonance (NMR) spectra and also biological activity through interaction with a plant receptor kinase, cytoplasmic calcium mobilization, andEscherichia coli in vivo root growth suppression. By contrast, RALF1 could only be isolated from inclusion bodies as a construct containing an N‐terminal His‐tag; its poorly resolved NMR spectrum was indicative of aggregation. We prepared samples of the RALF8 peptide labeled with15N and13C for NMR analysis and obtained near complete1H,13C, and15N NMR assignments; determined the disulfide pairing of its four cysteine residues; and examined its solution structure. RALF8 is mostly disordered except for the two loops spanned by each of its two disulfide bridges. -
Abstract Octreotide acetate, the active pharmaceutical ingredient in the long‐acting release (LAR) drug product Sandostatin®, is a cyclic octapeptide that mimics the naturally occurring somatostatin peptide hormone. Modern NMR can be a robust analytical method to identify and quantify octreotide molecules. Previous1H chemical shift assignments were mostly performed in organic solvents, and no assignments for heteronuclear13C,15N, and aromatic1H nuclei are available. Here, using state‐of‐the‐art 1D and 2D homo‐ and heteronuclear NMR experiments, octreotide was fully assigned, including water exchangeable amide protons, in aqueous buffer except for13CO and15NH of F1,15NH of C2, and15N
ζ Hζ of K5 that were not observed because of water exchange or conformational exchange. The solution NMR spectra were then directly compared with 1D1H/13C/15N solid‐state NMR (SSNMR) spectra showing the potential applicability of13C/15N SSNMR for octreotide drug product characterization.